Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Technologies, TGen to Launch Genetic Tests in US

NEW YORK (GenomeWeb) — Australian diagnostics firm Genetic Technologies said today that it has signed a memorandum of understanding to commercialize its range of polygenic risk tests in the US with the Translational Genomics Research Institute.

Under the terms of the deal, the partners will work together on a US commercialization strategy for Genetic Technologies' existing polygenic risk tests — which include its BrevaGenplus breast cancer risk assessment test — and future tests for indications in oncology, cardiovascular disease, and diabetes.

Genetic Technologies and Phoenix, Arizona-based TGen will also establish a joint US-based CLIA laboratory to offer the tests and work together to raise the funding necessary to support their alliance.

Additional terms were not disclosed.

"We are excited to be working with such a prestigious organization as TGen in bringing our current and developing future polygenic risk tests to the US market," Genetic Technologies Chairman Paul Kasian said in a statement.

Last summer, Genetic Technologies partnered with Beijing Zishan Health Consultancy on the establishment of a joint venture to offer its tests in China.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.